Stephen Ghiglieri is a veteran corporate officer of life science companies and a newly-appointed Managing Director of the Western Region for Danforth Advisors Big4Bio: As an experienced finance and operations executive, what attracted you to the life sciences? SG: I have spent the majority of my career in life sciences, but it was a departure […]
Moving Synthetic Biology Into the 21st Century
/ big4bio
In the second of four features on Molecular Assemblies, based on a conversation with CEO and President Mike Kamdar and Co-founder and Chief Scientific Officer Bill Efcavitch, Big4Bio takes a deeper look at the company’s enzymatic DNA synthesis technology, why it is needed, and the markets it serves. Companies to Watch – Molecular Assemblies by […]
Changing the Paradigm for Writing DNA
/ big4bio
In the first of four features on Molecular Assemblies, Big4Bio spoke with CEO and President Mike Kamdar and Co-founder and Chief Scientific Officer Bill Efcavitch about how the company got started, their technology for synthesizing DNA and why it is better than current methods, and their plans moving forward. The second feature will provide an […]
Spotlight: Explora BioLabs
/ big4bio
Leading the Nation’s Preclinical Vivarium Market Explora BioLabs provides preclinical, AAALAC-accredited vivarium space and related services to biotech clients in development stages from early startup to maturity. With nearly 200,000 square feet of space across 18 locations in biotech-dense communities, the company prides itself on providing clients the ability to initiate preclinical in vivo programs […]
The Big4Bio Company to Watch Program
September 2021: Molecular Assemblies
September 2021: Molecular Assemblies
/ big4bio
THE COMPANY/THE MISSION Changing the Paradigm for Writing DNA Molecular Assemblies’ leaders detail how the company got started, the company’s technology for synthesizing DNA, and why that technology is better than current methods. THE TECHNOLOGY Moving Synthetic Biology into the 21st Century A deeper look at the company’s enzymatic DNA synthesis technology, why […]
Sikich + Process Stream = Expanded Best of Breed Solutions Through a Company’s Journey
/ big4bio
Sikich LLP is a 1000-member business advisory firm that offers ERP and CRM technology and accounting services to a broad array of companies, including life sciences, tailored to fit their specific needs. In April 2021, Sikich acquired Process Stream, a leader in digital transformation services for regulated industries, which includes life sciences. The acquisition expands Sikich’s offerings […]
Q&A With Meissa Vaccines’ Board Chairperson, Kenneth J. Kelley
/ big4bio
In the final feature of Big4Bio’s Company to Watch program for July, we asked Meissa Vaccines’ Board Chairperson Kenneth J. Kelley about his predictions for Meissa and the importance of the company’s efforts. Briefly, tell me how you came to chair Meissa Vaccines’ Board of Directors. Marty Moore reached out to me first for advice […]
Podcast: How a Long Effort to Protect Against RSV May Lead to a Better COVID-19 Vaccine
/ big4bio
Company to Watch – Meissa Vaccines As part of July’s Company to Watch program, we spoke to Marty Moore, founder and CEO of Meissa Vaccines, about Meissa’s platform technology, how it works, and why its approach could provide significant benefits over existing COVID-19 vaccine. NEXT: A Q&A with Ken Kelley, Chairperson of the Board […]
Building Single Dose, Intranasal Vaccines to Prevent COVID-19 and RSV
/ big4bio
In the second of four features on Meissa Vaccines, Big4Bio explores the company’s technology and pipeline. Company to Watch – Meissa Vaccines When Marty Moore, Meissa Vaccines’ cofounder and CEO, is asked about why the company is advancing an intranasal recombinant live attenuated vaccine for COVID-19, he talks about the oral polio vaccine. Many remember […]
The Big4Bio Company to Watch Program
July 2021: Meissa Vaccines
July 2021: Meissa Vaccines
/ big4bio
THE COMPANY/THE MISSION Meissa Vaccines Is Driven to Rid the World of Viral Respiratory Scourges Meissa Vaccines is on a mission to solve a puzzle that has eluded scientists for decades—a pediatric vaccine against respiratory syncytial virus, or RSV. THE PIPELINE Building Single Dose, Intranasal Vaccines to Prevent COVID-19 and RSV Making vaccines […]
Meissa Vaccines Is Driven to Rid the World of Viral Respiratory Scourges
/ big4bio
In the first of four features on Meissa Vaccines, Big4Bio spoke with Meissa Vaccines CEO Marty Moore about Meissa’s drive to deliver vaccines against respiratory infections, the technology behind their pipeline, its relevance in today’s post-pandemic world, and what the future holds for the company. Company to Watch – Meissa Vaccines Marie Daghlian Meissa Vaccines […]
Spotlight: Mispro Biotech Services — Vivarium Services That Keep In Vivo Research In-House
/ big4bio
Mispro Biotech Services is a contract vivarium organization (CVO) that operates a network of full-service coworking vivarium facilities in all major U.S. and Canadian biotech hubs where emerging and established biopharma companies can conduct and control their own in vivo studies. Along with offering access to state-of-the-art vivarium research space, Mispro supports its clients with comprehensive animal care […]
Compassionate Capitalism
/ big4bio
In the final feature of Big4Bio’s Company to Watch program, we spoke with Venatorx Pharmaceuticals’ board member, Vincent Milano, about why he thinks the company is worth watching. Milano has more than 25 years of experience in biotechnology, first at ViroPharma, which was acquired by Shire, and currently as CEO of Idera Pharmaceuticals. Company to […]
A Discovery Engine That Keeps on Cranking
/ big4bio
Company to Watch – Venatorx Pharmaceuticals As May’s Company to Watch program concludes, Big4Bio shares thoughts from Venatorx’s Founder and Senior Vice President, Biology and Grants Development, Daniel Pevear, Ph.D., about why Venatorx is a company worth watching. by Marie Daghlian When Chris Burns, Luigi Xerri, and Dan Pevear left Novartis after it cut loose […]
Podcast: An Innovative Approach to Treating Multi-Drug Resistant Bacterial Infections
/ big4bio
Company to Watch – Venatorx Pharmaceuticals As part of May’s Company to Watch program, we spoke to Christopher Burns, founder, president, and CEO of Venatorx, about the need for new means of combating multi-drug resistant microbes, the company’s combination therapies in development, and its success at advancing its pipeline with non-dilutive funding. NEXT: […]